CD3xCD20 bispecific T-cell redirectors for relapsed or refractory B-cell lymphoma

被引：2
|
作者：
Ghobadi, Armin [1 ]
Bartlett, Nancy L. [1 ]
机构：
[1] Washington Univ, Sch Med, Siteman Canc Ctr, Div Oncol,Dept Med, St Louis, MO 63110 USA
来源：
LANCET | 2021年 / 398卷 / 10306期
关键词：
D O I：
10.1016/S0140-6736(21)01070-9
中图分类号：
R5 [内科学];
学科分类号：
1002 ; 100201 ;
摘要：
引用
收藏
页码：1109 / 1110
页数：3
相关论文
共 50 条
  • [31] Low mortality from COVID-19 infection in patients with B-cell lymphoma after bispecific CD20xCD3 therapy
    Kyvsgaard, Emil R.
    Riley, Caroline
    Clausen, Michael Roost
    Harslof, Mads
    Heftdal, Line Dam
    Niemann, Carsten U.
    Gronbaek, Kirsten
    Hutchings, Martin
    Husby, Simon
    BRITISH JOURNAL OF HAEMATOLOGY, 2024, 204 (01) : 356 - 360
  • [32] Open-Label Phase 2 Study Of The Bispecific T-Cell Engager (BiTE®) Blinatumomab In Patients With Relapsed/Refractory Diffuse Large B-Cell Lymphoma
    Viardot, Andreas
    Goebeler, Mariele
    Pfreundschuh, Michael
    Adrian, Nicole
    Libicher, Martin
    Degenhard, Evelyn
    Stieglmaier, Julia
    Zhang, Alicia
    Nagorsen, Dirk
    Bargou, Ralf C.
    BLOOD, 2013, 122 (21)
  • [33] Role of Bispecific Antibodies in Relapsed/Refractory Diffuse Large B-Cell Lymphoma in the CART Era
    Barca, Eva Gonzalez
    FRONTIERS IN IMMUNOLOGY, 2022, 13
  • [34] OUTCOMES OF COMMERCIAL AND IN-HOUSE ANTI CD19 CAR T-CELL THERAPY FOR RELAPSED/REFRACTORY B-CELL LYMPHOMA IN SINGAPORE
    Ong, Shin Yeu
    Krisnadi, Cindy
    Wang, Samuel Sherng Young
    Chen, Yun Xin
    Seng, Michaela Su-fern
    Soh, Shui Yen
    Chan, Esther Hian Li
    Hwang, William Ying Khee
    Ho, Aloysius Yew Leng
    Lim, Francesca Lorraine Wei Inng
    BONE MARROW TRANSPLANTATION, 2024, 59 : 226 - 226
  • [35] Molecular Disease Monitoring in Patients With Relapsed/refractory B-Cell Lymphoma Receiving Anti-CD19 CAR T-Cell Therapy
    Colton, Meryl
    Purev, Enkhtsetseg
    Haverkos, Bradley
    Bair, Steven
    Jasem, Jagar
    Jacob, Allison
    Kamdar, Manali
    CLINICAL LYMPHOMA MYELOMA & LEUKEMIA, 2024, 24 (11): : 778 - 782
  • [36] ACTR707: a novel T-cell therapy for the treatment of relapsed or refractory CD20+B cell lymphoma in combination with rituximab
    Motz, Greg
    Whiteman, Kathleen
    Shin, John
    Pai, Tapasya
    Judge, Casey
    Barnitz, Anthony
    Hemphill, James
    Kim, James
    Ranger, Ann
    Huet, Heather
    McGinness, Kathleen
    Schultes, Birgit
    Hodge, Geoffrey
    Vasconcelles, Michael
    Ettenberg, Seth
    MOLECULAR CANCER THERAPEUTICS, 2018, 17 (01)
  • [37] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients With Relapsed or Refractory Large B-Cell Lymphoma
    不详
    CLINICAL ADVANCES IN HEMATOLOGY & ONCOLOGY, 2019, 17 (05) : 15 - 17
  • [38] Translating anti-CD19 CAR T-cell therapy into clinical practice for relapsed/refractory diffuse large B-cell lymphoma
    Chow, Victor A.
    Shadman, Mazyar
    Gopal, Ajay K.
    BLOOD, 2018, 132 (08) : 777 - 781
  • [39] Safety of Axicabtagene Ciloleucel CD19 CAR T-Cell Therapy in Elderly Patients with Relapsed or Refractory Large B-Cell Lymphoma
    Sano, Dahlia
    Nastoupil, Loretta J.
    Fowler, Nathan H.
    Fayad, Luis
    Hagemeister, F. B.
    Lee, Hun Ju
    Samaniego, Felipe
    Wang, Michael
    Rodriguez, Maria Alma
    Iyer, Swaminathan P.
    Parmar, Simrit
    Steiner, Raphael
    Nair, Ranjit
    Adkins, Sherry
    Arafat, Sara
    Rao, Ahalya
    Vallejo, Liliana
    Hawkins, Misha
    Chen, Yiming
    Westin, Jason R.
    Neelapu, Sattva S.
    BLOOD, 2018, 132
  • [40] Successful treatment of relapsed acute B-cell lymphoblastic leukemia with CD20/CD22 bispecific chimeric antigen receptor T-cell therapy
    Liang, Zuyu
    Cui, Jiazhen
    Chang, Alex Hongsheng
    Yu, Jian
    Hu, Yongxian
    Huang, He
    REGENERATIVE THERAPY, 2020, 15 : 281 - 284
12345